Inogen Q2 revenue down 19% to $83.6M; net loss widens to $9.8M

Inogen Inc

2023-Q2 EPS reported -$1.31 revenue$155,797,000

Total revenue $83.6M, down 19.1% YoY; GAAP net loss $9.8M vs $3.4M loss year ago.
Adjusted net loss $5.8M; Adjusted EBITDA loss $3.2M (vs positive $3.2M in Q2 2022).
Entered agreement to acquire Physio-Assist to add airway clearance market opportunity.
Introduced Inogen Rove 6 portable oxygen concentrator with 8-year expected service life.
Cash, cash equivalents and marketable securities $170.1M; no debt outstanding.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Inogen Inc reported second quarter ended June 30, 2023 results: net income Adjusted net loss of $5.8 million.

Period: second quarter ended June 30, 2023
Net income: Adjusted net loss of $5.8 million
Result: reported results

Exact text from the filing

Adjusted net loss was $5.8 million compared to Adjusted net loss of $0.4 million in the second quarter of 2022.

View on SEC.gov

Browse all earnings releases →

Inogen Inc filing history →

Source: SEC EDGAR

accession 0000950170-23-039037

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.